Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameUni Health
Stock Code02211
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們為中國東北地區領先的醫藥零售商及分銷商,擁有中國東北地區最大的醫藥零售連鎖網絡,並為中國東北地區最大的民營醫藥分銷商
Listing Date2013-12-12
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國瀋陽鐵西區保工北街15號
Business Address (Hong Kong)香港皇后大道中15號置地廣場告羅士打大廈8樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitejtyyjt.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 2.91 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer Period2013-12-02 to 2013-12-05
Global Offering Shares500,000,000 shares
HK Public Offer Shares (Initial)50,000,000 shares (10.0%)
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)450,000,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO1,999,999,999 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone ShareNo cornerstone investors
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 1,455,000,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
HK Market Cap HK$ 411.9M
Est. Threshold HK$ 9.37B
Analysis Result HK market cap below threshold, need +2175%

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利約人民幣228百萬元
Period-End Cash Balance人民幣455.9百萬元
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 2010201120122013-06
Revenue 858,6131,473,9022,326,2921,456,990
Cost of sales -618,872-1,095,758-1,780,523-1,073,274
Gross profit 239,741378,144545,769383,716
Other income and gains, net 2,2094821,12228
Selling and distribution expenses -67,323-103,010-188,887-137,763
Administrative expenses -11,625-30,743-41,974-30,248
Operating profit 160,916244,848301,755214,497
Net finance costs -34-79-188-157
Share of associates and JVs 06321,137808
Profit before tax 163,605251,223305,880217,573
Income tax expense -41,095-62,377-78,517-53,527
Profit for the year 122,510188,846227,363164,046
Profit attributable to owners 122,510180,117213,760150,780
Balance Sheet
Item 2010201120122013-06
Cash and cash equivalents 107,025713,257455,916592,868
Trade and bills receivables 75,281209,579273,730237,111
Inventories 80,593177,929249,442270,879
Total current assets 262,8991,100,7651,098,5201,109,125
Total assets 268,8301,232,7691,515,1461,657,421
Total current liabilities 81,718826,960862,119860,975
Total liabilities 81,718831,525886,988884,915
Total equity 187,112401,244628,158772,506
Equity attributable to owners 187,112362,457548,781688,313
Cash Flow Statement
Item 2010201120122013-06
Net cash from operating activities 107,378121,795161,628170,225
Net cash from investing activities 35,534-179,022-323,421-34,222
Net cash from financing activities -105,834663,799-95,5312,061
Net increase in cash 37,078606,572-257,324138,064
Purchase of PP&E -1,030-11,742-14,537-38,023
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 2.37
First Day OpenHK$ 1.99
First Day Change-18.56%
First Day Volume208939000.0
First Day Turnover515674000.0
Use of Proceeds
(1) 所得款項凈額約40%將用作為我們于中國(尤其中國東北地區)收購擴張提供資金。截至最后實際可行日期,我們并無物色到任何收購對象; (2) 所得款項凈額約30%將用作為我們的內生增長提供資金,內生增長包括新設藥店以及升級我們現有的物流中心及額外設立物流中心; (3) 所得款項凈額約20%將用作推廣金天愛心、授權品牌及授權品牌產品。根據本集團所 采用的價值鏈整合模式,授權品牌產品相關的推廣和營銷工作通常由分銷商(而非制造商)進行,因為分銷商能夠直接接觸下游客戶。 (4) 所得款項凈額約10%將用作營運資金。

Underwriting Syndicate

Sole Sponsor (1)
Morgan Stanley Asia Limited CE AAD291
Overall Coordinators (1)
Morgan Stanley Asia Limited CE AAD291
Joint Bookrunners (3)
Morgan Stanley Asia Limited CE AAD291 星展亚洲融资有限公司 CE AAE430 交银国际证券有限公司 CE APJ121

Cornerstone Investors

This stock has no cornerstone investors.

Directors & Management

PositionChinese nameEnglish Name
Chairman金東濤—
Company Secretary葛俊明、翁美儀—
No director data available.

Major Shareholders

Major Shareholders & Holdings最終控股股東為金先生
About this page

This page shows Uni Health (02211) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect